Compare SNV & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SNV | KRYS |
|---|---|---|
| Founded | 1888 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 6.3B |
| IPO Year | N/A | 2017 |
| Metric | SNV | KRYS |
|---|---|---|
| Price | $48.44 | $216.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 9 |
| Target Price | $58.74 | ★ $214.22 |
| AVG Volume (30 Days) | ★ 900.4K | 325.5K |
| Earning Date | 01-14-2026 | 11-03-2025 |
| Dividend Yield | ★ 3.22% | N/A |
| EPS Growth | 143.15 | ★ 275.72 |
| EPS | 5.35 | ★ 6.66 |
| Revenue | ★ $2,291,796,000.00 | $373,164,000.00 |
| Revenue This Year | $30.36 | $34.33 |
| Revenue Next Year | $4.80 | $48.04 |
| P/E Ratio | ★ $9.06 | $32.72 |
| Revenue Growth | 31.11 | ★ 54.51 |
| 52 Week Low | $35.94 | $122.80 |
| 52 Week High | $61.06 | $221.84 |
| Indicator | SNV | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 60.21 | 70.43 |
| Support Level | $43.80 | $213.24 |
| Resistance Level | $49.46 | $221.84 |
| Average True Range (ATR) | 1.35 | 6.84 |
| MACD | 0.44 | 0.66 |
| Stochastic Oscillator | 80.91 | 78.79 |
Synovus Financial Corp provides commercial and consumer banking in addition to a full suite of specialized products & services such as private banking, treasury management, wealth management, mortgage services, premium finance, asset-based lending, structured lending, capital markets, & international banking to clients through the wholly-owned subsidiary bank, Synovus Bank, and other offices in Alabama, Florida, Georgia, South Carolina, and Tennessee. It has four segments Wholesale Banking, Community Banking, Consumer Banking, and Financial Management Services, out of which the majority is from the Wholesale banking segment.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.